* Phase lll study of mepolizumab meets co-primary endpoints
and all secondary endpoints in patients with eosinophilic
granulomatosis with polyangiitis
The post BRIEF-GSK’s Mepolizumab meets endpoints in phase 3 EGPA study appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Phase lll study of mepolizumab meets co-primary endpoints
and all secondary endpoints in patients with eosinophilic
granulomatosis with polyangiitis
The post BRIEF-GSK’s Mepolizumab meets endpoints in phase 3 EGPA study appeared first on NASDAQ.